Tilak Healthcare company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series A | Alive

Total Raised


Last Raised

$8.18M | 10 mos ago

About Tilak Healthcare

Tilak Healthcare specializes in digital healthcare and is dedicated to the development of medically-prescribed video games for the monitoring and follow-up of patients suffering from chronic diseases. The company's application targets ophthalmology with macular diseases, which affect a large number of patients in the aging populations of developed countries.

Tilak Healthcare Headquarter Location

74 Rue du Faubourg Saint-Antoine

Paris, 75012,


ESPs containing Tilak Healthcare

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Healthcare Payers Tech

Companies in this market develop digital therapeutics to treat various ophthalmological conditions, such as amblyopia, myopia, and visual impairments from brain injuries. Many of them are developing video games — accessed through mobile apps or virtual reality headsets — that help improve visual acuity.

Tilak Healthcare named as Leader among 5 other companies, including S-Alpha Therapeutics, Vivid Vision, and Nunaps.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tilak Healthcare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tilak Healthcare is included in 4 Expert Collections, including Digital Health.


Digital Health

13,504 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


Medical Devices

8,452 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Tilak Healthcare Patents

Tilak Healthcare has filed 2 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
  • Graphical control elements
patents chart

Application Date

Grant Date


Related Topics




Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces


Application Date


Grant Date



Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces



Latest Tilak Healthcare News

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities

Feb 24, 2022

Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities Voluntis Announces Partnership with Tilak Healthcare to Help Patients with Cancer Better Manage Ocular Toxicities Cambridge, Massachusetts, February 23, 2022 - Voluntis, an Aptar Pharma company and leader in digital therapeutics , today announced a partnership with Tilak Healthcare, a digital therapeutics company specializing in clinically validated medical mobile apps for chronic diseases. Under this new collaboration, both companies will combine Tilak’s OdySight® Care™ mobile app with Voluntis’ Theraxium platform to offer a vision-screening solution for patients living with cancer. This new solution will give patients of Voluntis’ digital therapeutics (DTx) platform access to OdySight® Care™ and the possibility to measure their visual health anytime and anywhere. Once they have tested their vision using the OdySight® Care™ application on their mobile device, patients will receive a clinically-validated visual acuity score in real time, providing them with medical advice and guidance relating to their ophthalmic health. Certain anti-cancer treatments such as chemotherapy or targeted immunotherapy are known for causing eye-related issues in some patients. Although ocular side effects such as a decrease in sharpness of vision may affect a patient’s quality of life and the ability to perform daily tasks such as reading or driving, most eye-related disorders caused by medical treatments can be managed with appropriate visual screening, monitoring or the adjustment of treatment doses. Therefore, this new integrated solution, which provides a digital testing tool for cancer patients to self-assess their visual acuity while undergoing treatment, may help improve patient care and could ultimately reduce the potential risk of treatment discontinuation. “We welcome this new partnership with Voluntis to expand our solutions to new specialties, where visual acuity testing - thanks to the existing OdySight® platform, which now includes OdySight® Care™ - can help manage the follow-up of patients. It is a key milestone in our technology platform development and we are excited to provide visual acuity testing to patients through the Theraxium platform,” said Edouard Gasser, CEO, Tilak Healthcare   “We are pleased to announce our new collaboration with Tilak Healthcare, which will expand Theraxium's capabilities and integrate our platform into a broader digital health ecosystem. This collaboration represents a new opportunity for patients to screen their visual acuity, and access a better follow-up for their treatment-related symptoms,” added Pierre Leurent, CEO, Voluntis and President, Aptar Pharma Digital Health. This new collaboration further underlines Voluntis’ vision to create a comprehensive ecosystem of sensors and digital biomarkers around its DTx platform. Through such partnerships, Voluntis will make these advanced capabilities available to its life sciences partners, offering adaptable, turnkey digital therapeutic solutions which aim to continuously improve the patient experience. Tilak Healthcare is a unique mobile app studio where like-minded and passionate people create mobile medical apps for patients with chronic diseases. There is an ever-increasing demand for medical services, placing a huge burden on the healthcare system; doctors and caregivers need new, validated tools and resources to improve access. At Tilak Healthcare, every product on the market is clinically validated, developed with physician and patient advocates, compliant with medical device regulations, and protects the patient’s privacy. For more information, please visit http://www.tilakhealthcare.com/ . Voluntis is an Aptar Pharma company and part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions combine mobile and web apps, using clinical algorithms to deliver personalized recommendations to patients and their care teams to adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis designs digital therapeutics solutions across multiple areas, including oncology and diabetes. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance. For more information, please visit: www.voluntis.com and www.aptar.com . Editor Details

Tilak Healthcare Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Tilak Healthcare Rank

  • When was Tilak Healthcare founded?

    Tilak Healthcare was founded in 2016.

  • Where is Tilak Healthcare's headquarters?

    Tilak Healthcare's headquarters is located at 74 Rue du Faubourg Saint-Antoine, Paris.

  • What is Tilak Healthcare's latest funding round?

    Tilak Healthcare's latest funding round is Series A.

  • How much did Tilak Healthcare raise?

    Tilak Healthcare raised a total of $10.9M.

  • Who are the investors of Tilak Healthcare?

    Investors of Tilak Healthcare include iBionext, Elaia Partners, SWEN Capital Partners, Matmut Innovation and Plug and Play Accelerator.

  • Who are Tilak Healthcare's competitors?

    Competitors of Tilak Healthcare include S-Alpha Therapeutics and 6 more.

You May Also Like

S-Alpha Therapeutics

S-Alpha Therapeutics is a digital therapeutics company with platform technologies that enable digital devices to treat different diseases. S-Alpha has a pipeline of products in the areas of ophthalmology, neuropsychiatry, cancer, and immunology.

Caterna Logo

Caterna develops and markets Software-as-a-Service (SaaS) telemetric treatment software for therapeutic applications in ophthalmology.

Luminopia Logo

Luminopia uses virtual reality goggles to correct amblyopia or lazy eye. Its technology also holds the potential to provide a way to detect this condition, which can frequently go undiagnosed.


Dopavision develops a digital therapeutic that aims to slow down myopia progression in children and adolescents through the activation of dopamine.

Vivid Vision Logo
Vivid Vision

Vivid Vision is a VR game for people with amblyopia (lazy eye) as well as strabismus (crossed eye).


Nunaps is a digital therapeutics company that develops Nunaps Vision, a VR software that treats visual impairment after brain injury.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.